bPiDI is a novel selective alpha6beta2 nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with alpha6beta2-containing nAChRs[1].
Molecular Weight:
580.33
Purity:
99.65
CAS Number:
[525596-64-9]
Formula:
C22H34I2N2
Target:
nAChR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted